James R. Downing’s decision to step down in 2026 marks the end of a transformative era for St. Jude Children’s Research Hospital, even as he continues its global mission in a new role.
St. Jude Children’s Research Hospital announced that James R. Downing, MD, will step down as president and CEO in late 2026, concluding a 12-year tenure that coincided with one of the institution’s most ambitious periods of growth. Downing, who first joined St. Jude in 1986, will transition to a faculty position in the Department of Pediatric Global Medicine, reflecting his long-standing focus on expanding the hospital’s international reach.
The leadership change is planned rather than abrupt, with Downing remaining in place while the Board of Governors conducts a global search for his successor. The board expects to name a new CEO this summer, with a full handoff by the end of next year. That extended timeline suggests a desire for continuity at an organization whose work blends scientific research, patient care, and a distinctive philanthropic model.
Downing’s tenure as CEO began in 2014, but his influence on pediatric cancer research stretches back decades. As a scientist, he helped pioneer understanding of the genetic basis of childhood leukemia and played a key role in launching the Pediatric Cancer Genome Project, which advanced genome sequencing in pediatric oncology. Under his leadership, St. Jude also invested heavily in data science, opened new research centers, and broadened its clinical footprint in Memphis, including new patient housing and clinical towers.
Perhaps most significantly, Downing oversaw efforts to extend St. Jude’s impact beyond the United States. The establishment of St. Jude Global and partnerships with organizations such as the World Health Organization positioned the hospital as a central player in international childhood cancer initiatives. The institution’s overall strategic plans during his tenure called for nearly $20 billion in investments and the addition of more than 2,300 positions, underscoring the scale of its expansion.
The transition comes at a time when childhood cancer survival rates have improved dramatically over the past several decades, a shift to which St. Jude has contributed. Downing’s move into global pediatric medicine suggests that, even as new leadership prepares to take the helm, the institution’s outward-looking mission will remain central to its next chapter.
